GGrantIndex
← Leaderboards

Xingmin Sun

Tufts University Boston

$6,236,829
Attributed
$9,487,471
Total exposure
8
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY201225
$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,487,471 · 8

By mechanism

R01$7,578,103 · 3
R21$1,285,359 · 3
K01$470,429 · 1
R03$153,580 · 1

Top collaborators

Most similar at Tufts University Boston

Same institution · by research overlap

Others in their field

Top investigators on “Infection

Research focus

InfectionClostridium DifficileToxinAntibioticsRecurrenceResistanceReproduction SporesMouse ModelPreventIntestinesPlayProteinsResponsePseudomembranous ColitisCenters For Disease Control And Prevention (U.S.)Cessation Of LifeDesignReportingDiarrheaCellsHamstersAntibodiesOralEnteric Pathogen

Grant awards (29)

Clostridioides difficile Zinc-binding PBPs as anti-sporulation targets$2,872,722
R01 · FY2025 · AI
Multivalent vaccines against Clostridioides difficile infection$448,630
R01 · FY2025 · AI · contact PI
Development of probiotic-based and Clostridioides difficile-targeted therapeutics$190,313
R21 · FY2025 · AI · contact PI
Multivalent vaccines against Clostridioides difficile infection$464,294
R01 · FY2024 · AI · contact PI
Development of probiotic-based and Clostridioides difficile-targeted therapeutics$240,875
R21 · FY2024 · AI · contact PI
Novel polymer biomaterials combating C. difficile infection$373,750
R01 · FY2023 · AI
Novel polymer biomaterials combating C. difficile infection$373,750
R01 · FY2022 · AI
Effect of bile salt hydrolase inhibitors on Clostridium difficile infection$184,250
R21 · FY2022 · AI
Multivalent vaccines against Clostridium difficile infection$379,925
R01 · FY2021 · AI · contact PI
Novel polymer biomaterials combating C. difficile infection$373,750
R01 · FY2021 · AI
Effect of bile salt hydrolase inhibitors on Clostridium difficile infection$231,450
R21 · FY2021 · AI
Multivalent vaccines against Clostridium difficile infection$379,863
R01 · FY2020 · AI · contact PI
Novel polymer biomaterials combating C. difficile infection$373,750
R01 · FY2020 · AI
Multivalent vaccines against Clostridium difficile infection$379,803
R01 · FY2019 · AI · contact PI
Novel polymer biomaterials combating C. difficile infection$373,750
R01 · FY2019 · AI
Multivalent vaccines against Clostridium difficile infection$382,035
R01 · FY2018 · AI · contact PI
The role of tumor progression locus 2 (TPL2) in the pathogenesis of Clostridium difficile infection (CDI)$76,790
R03 · FY2018 · DK · contact PI
Multivalent vaccines against Clostridium difficile infection$402,081
R01 · FY2017 · AI · contact PI
The role of tumor progression locus 2 (TPL2) in the pathogenesis of Clostridium difficile infection (CDI)$76,790
R03 · FY2017 · DK · contact PI
Multivalent Bacillus mucosal vaccines against Clostridium difficile infection$229,600
R21 · FY2016 · AI · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$93,925
K01 · FY2016 · DK · contact PI
Multivalent Bacillus mucosal vaccines against Clostridium difficile infection$132,621
R21 · FY2015 · AI · contact PI
Multivalent Bacillus mucosal vaccines against Clostridium difficile infection$76,250
R21 · FY2015 · AI · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$71,593
K01 · FY2015 · DK · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$22,332
K01 · FY2015 · DK · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$93,925
K01 · FY2014 · DK · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$93,925
K01 · FY2013 · DK · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$804
K01 · FY2013 · DK · contact PI
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CD$93,925
K01 · FY2012 · DK · contact PI